Overall, the goal of expanded facility is to strengthen [SK biosciences] manufacturing capabilities for global supply [of the pneumococcal conjugate vaccine candidate
SK bioscience has announced its manufacturing plant L HOUSE, in Andong, Gyeongsangbuk-do,
Overall, the goal of expanded facility is to strengthen its manufacturing capabilities for global supply, SK bioscience stated. Two floors will be added to the facility's existing vaccine manufacturing department. This will generate approximately 4,200m2 of new space, SK bioscience explained. The firm shared that following the facility expansion, it plans to obtain current good manufacturing practice (cGMP) certification for the new facility.
Promise of the pneumococcal conjugate vaccine
SK bioscience and
Prior to this new facility expansion, SK bioscience highlighted that in 2021, L HOUSE was the first domestic vaccine manufacturing facility to achieve EU-GMP certification from the
Harnessing market potential following the facility expansion
The pneumococcal vaccine market is predicted to value
[The] expanded manufacturing facility [is planned to support] introduction of the pneumococcal conjugate vaccine into the worldwide market”
SK bioscience shared that together with
Following the facility expansion, L HOUSE will "firmly establish itself as a global vaccine hub… We will make every effort to achieve successful development and supply of a vaccine with blockbuster potential,”
According to the
The post Manufacturing facility expansion to advance next-gen vaccine appeared first on European Pharmaceutical Review.
© Russell Publishing Limited, 2024. All Rights Reserved., source